These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39132909)

  • 1. Sample Size Calculation Under Nonproportional Hazards Using Average Hazard Ratios.
    Dormuth I; Pauly M; Rauch G; Herrmann C
    Biom J; 2024 Sep; 66(6):e202300271. PubMed ID: 39132909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
    Tang Y
    Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch G; Brannath W; Brückner M; Kieser M
    Methods Inf Med; 2018 May; 57(3):89-100. PubMed ID: 29719915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
    Wang Z; Zhang Q; Xue A; Whitmore J
    Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints.
    Cortés Martínez J; Geskus RB; Kim K; Melis GG
    BMC Med Res Methodol; 2021 May; 21(1):99. PubMed ID: 33957892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sample size formula for the supremum log-rank statistic.
    Eng KH; Kosorok MR
    Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring.
    Schaubel DE; Wei G
    Biometrics; 2011 Mar; 67(1):29-38. PubMed ID: 20560935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential tests for non-proportional hazards data.
    Brückner M; Brannath W
    Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
    Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
    JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of survival distributions in clinical trials: A practical guidance.
    Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
    Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
    Jachno K; Heritier S; Wolfe R
    BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H; He J
    Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
    Yang S
    Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power and sample size calculation for log-rank test with a time lag in treatment effect.
    Zhang D; Quan H
    Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study to alternatives to the log-rank test.
    Dormuth I; Liu T; Xu J; Pauly M; Ditzhaus M
    Contemp Clin Trials; 2023 May; 128():107165. PubMed ID: 36972865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
    Xiong X; Wu J
    Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size calculation for studies with grouped survival data.
    Li Z; Wang X; Wu Y; Owzar K
    Stat Med; 2018 Nov; 37(27):3904-3917. PubMed ID: 29888484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for non-proportional hazards in clinical trials: A systematic review.
    Bardo M; Huber C; Benda N; Brugger J; Fellinger T; Galaune V; Heinz J; Heinzl H; Hooker AC; Klinglmüller F; König F; Mathes T; Mittlböck M; Posch M; Ristl R; Friede T
    Stat Methods Med Res; 2024 Jun; 33(6):1069-1092. PubMed ID: 38592333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.